Racura Oncology Ltd (ASX: RAC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Racura Oncology Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$403.01 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
181.54 million
Earnings per share
-0.028
Dividend per share
N/A
Year To Date Return
-19.41%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Racura Oncology Ltd (ASX: RAC)
Latest News
Healthcare Shares
Why the Race Oncology (ASX:RAC) share price surged 7% today
Share Gainers
Why is the Race Oncology (ASX:RAC) share price up 18% in a month?
Healthcare Shares
What's going on with the Race Oncology (ASX:RAC) share price today?
Share Market News
Race Oncology (ASX:RAC) share price slumps on quarterly update
Healthcare Shares
The 5 best performing ASX healthcare shares of FY21, did yours make the cut?
Healthcare Shares
The Race Oncology (ASX:RAC) share price is stumbling today
Share Gainers
Why the Race Oncology (ASX:RAC) share price is charging higher today
Share Gainers
Why Ecofibre, MoneyMe, Nearmap, & Race Oncology shares are storming higher
Healthcare Shares
Here's why the Race Oncology (ASX:RAC) share price is leaping higher
Healthcare Shares
Why the Race Oncology (ASX:RAC) share price is frozen
Share Gainers
Why the Race Oncology (ASX:RAC) share price is racing higher
Share Gainers
Why Ampol, Netwealth, Orocobre, & Race Oncology shares are storming higher
Frequently Asked Questions
-
No, Racura Oncology does not pay dividends at this time.
-
Sydney-headquartered Racura Oncology listed on the ASX on 13 July 2016.
RAC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Racura Oncology Ltd
Racura Oncology (ASX: RAC) is a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care.
Racura’s lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1.
Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase 3 clinical programs in acute myeloid leukaemia (AML), Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.
Racura Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle. Racura is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world.
RAC Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Feb 2026 | $2.22 | $0.02 | 0.91% | 112,341 | $2.20 | $2.30 | $2.15 |
| 19 Feb 2026 | $2.20 | $-0.02 | -0.90% | 101,703 | $2.24 | $2.24 | $2.17 |
| 18 Feb 2026 | $2.22 | $0.05 | 2.30% | 108,383 | $2.17 | $2.29 | $2.17 |
| 17 Feb 2026 | $2.17 | $-0.02 | -0.91% | 81,827 | $2.20 | $2.20 | $2.13 |
| 16 Feb 2026 | $2.19 | $0.04 | 1.86% | 152,514 | $2.15 | $2.20 | $2.05 |
| 13 Feb 2026 | $2.15 | $-0.10 | -4.44% | 193,696 | $2.25 | $2.25 | $2.13 |
| 12 Feb 2026 | $2.25 | $-0.15 | -6.25% | 72,400 | $2.40 | $2.40 | $2.25 |
| 11 Feb 2026 | $2.40 | $-0.05 | -2.04% | 173,607 | $2.41 | $2.47 | $2.33 |
| 10 Feb 2026 | $2.45 | $0.16 | 6.99% | 108,691 | $2.30 | $2.45 | $2.26 |
| 09 Feb 2026 | $2.29 | $0.04 | 1.78% | 64,333 | $2.25 | $2.38 | $2.25 |
| 06 Feb 2026 | $2.25 | $-0.05 | -2.17% | 183,071 | $2.27 | $2.29 | $2.16 |
| 05 Feb 2026 | $2.30 | $0.01 | 0.44% | 118,021 | $2.30 | $2.33 | $2.27 |
| 04 Feb 2026 | $2.29 | $0.04 | 1.78% | 93,707 | $2.26 | $2.31 | $2.22 |
| 03 Feb 2026 | $2.25 | $0.04 | 1.81% | 178,451 | $2.10 | $2.30 | $2.10 |
| 02 Feb 2026 | $2.21 | $-0.02 | -0.90% | 146,443 | $2.29 | $2.30 | $2.14 |
| 30 Jan 2026 | $2.23 | $0.01 | 0.45% | 247,953 | $2.23 | $2.28 | $2.19 |
| 29 Jan 2026 | $2.22 | $-0.20 | -8.26% | 556,883 | $2.40 | $2.42 | $2.18 |
| 28 Jan 2026 | $2.42 | $-0.02 | -0.82% | 284,583 | $2.44 | $2.48 | $2.31 |
| 27 Jan 2026 | $2.44 | $-0.22 | -8.27% | 392,869 | $2.70 | $2.70 | $2.40 |
| 23 Jan 2026 | $2.66 | $-0.07 | -2.56% | 167,931 | $2.79 | $2.79 | $2.63 |
| 22 Jan 2026 | $2.73 | $0.00 | 0.00% | 214,480 | $2.74 | $2.83 | $2.72 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 13 Feb 2026 | Daniel Tillett | Sell | 14,000 | $30,100 |
On-market trade.
|
| 11 Feb 2026 | Daniel Tillett | Buy | 62,631 | $150,314 |
On-market trade.
|
| 22 Jan 2026 | Daniel Tillett | Exercise | 400,000 | $500,000 |
Exercise of options.
|
| 22 Jan 2026 | Daniel Tillett | Buy | 400,000 | $500,000 |
Exercise of options.
|
| 18 Dec 2025 | Daniel Tillett | Buy | 300,000 | $375,000 |
Exercise of options. 17,760,160 prior Holding
|
| 18 Dec 2025 | Daniel Tillett | Buy | 12,218 | $31,529 |
On-market trade.
|
| 18 Dec 2025 | Daniel Tillett | Exercise | 300,000 | $375,000 |
Exercise of options.
|
| 26 Nov 2025 | Daniel Tillett | Buy | 22,000 | $58,744 |
On-market trade. As per announcement
|
| 26 Nov 2025 | Peter (Pete) Smith | Buy | 9,433 | $25,027 |
On-market trade.
|
| 25 Nov 2025 | Serge Scrofani | Issued | 23,983 | $69,790 |
Issue of options.
|
| 25 Nov 2025 | Peter (Pete) Smith | Issued | 357,162 | $1,039,341 |
Issue of options.
|
| 25 Nov 2025 | Megan Baldwin | Issued | 45,470 | $132,317 |
Issue of options.
|
| 25 Nov 2025 | Daniel Tillett | Issued | 903,225 | $2,628,384 |
Issue of options. As per announcement on 25-11-2025
|
| 25 Nov 2025 | Daniel Tillett | Exercise | 2,000,000 | $5,820,000 |
Exercise of options. Cashless exercise
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Megan Baldwin | Non-Executive Director | Jan 2025 |
Dr Baldwin has more than 25 years of experience working on therapeutic drug development programs for oncology and ophthalmic indications. She was the Founder and Chief Innovation Officer of Opthea Limited (ASX:OPT; NASDAQ:OPT). Prior to Opthea, Dr Baldwin was previously employed at Genentech (now Roche) as a researcher before moving to Genentech's commercial division. Dr Baldwin's experience in oncology drug development includes both preclinical and clinical investigation of inhibitors targeting angiogenic factors involved in tumour growth and spread, as well as management of competitive intelligence activities to support Genentech's early stage oncology programs. Dr Baldwin currently serves on the boards of Anaxis Pharma,Gertrude Biomedical, and AusBiotech. Other Directorships held include Invex Therapeutics (from 1 February 2021 to 30 June 2024).
|
| Dr Daniel Tillett | Chief Executive OfficerManaging Director | Sep 2019 |
Dr Tillett is the CEO and founder of Nucleics Pty Ltd, a private Australian biotechnology company producing and selling DNA sequencing software to the genomics industry. Nucleics SAAS (software as a service) genomics tools are used in more than 30 countries and at over 250 companies and research institutions. Dr Tillett was previously an Executive Director and Chief Scientific Officer at Race from 17 September 2019 and 1 October 2019, respectively and resigned from both roles on 21 March 2023. Dr Tillett was a Senior Lecturer within the School of Pharmacy at La Trobe University where he taught and researched in the areas of pharmacy, phage therapy, virology, microbiology, bioinformatics and cancer. He has more than 40 scientific publications and granted patents in molecular biology, virology, microbiology, genetics and biochemistry. Other Directorships include Simble Solutions Limited (Non Executive Director appointed 16 February 2022, resigned 3 July 2023); Tryptamine Therapeutics Limited (Non-Executive Director, appointed 8 November 2024).
|
| Dr Peter (Pete) Smith | Executive DirectorExecutive Chairman | Jun 2023 |
Dr Smith has over 35 years of experience in the pharmaceutical and biotech industry, with a focus on therapeutics, especially oncology. He has been involved in projects at all stages from concept to phase III clinical studies and drug approval. He was previously the CEO of private biotechnology company Myrio Therapeutics, and publicly listed Australian companies Alchemia and AMRAD. Prior to moving to Australia, Dr Smith co-founded and was Chief Financial Officer of Onyvax Ltd, a cancer immunotherapy company based in London. At the start of his career, he was a top-rated Pharmaceuticals Analyst with UBS and HSBC, being involved in numerous transactions including LSE/NASDAQ initial public offerings, fundraisings, and M&A. He is also currently a Director of Amala Therapeutics.
|
| Dr Serge Scrofani | Non-Executive Director | Sep 2024 |
Dr Scrofani has more than 28 years' experience in the healthcare sector, working in global roles across research and strategy, and corporate and business development. He served as Vice President of Strategy & Corporate Development at CSL for 13 years where he played a role in multiple strategic initiatives including the company's global COVID-19 response and its $US11.7 billion acquisition of Vifor Pharma AG. Prior to this, he led Business Development for subsidiary CSL Behring, based in the United States (US). Serge is currently CEO and Managing Director of FinCap Group Holdings Pty Ltd, an Australian private investment firm. He is also a Board member of the Burnet Institute and The Centre for Eye Research. Serge undertook postdoctoral research studies at The University of Melbourne and completed a Fulbright postdoctoral fellowship at The Scripps Research Institute, La Jolla California.
|
| Mr Peter Webse | Company Secretary | Aug 2016 |
-
|
| Peter Webse | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Dr Daniel Tillett | 17,267,615 | 9.94% |
| Mr Phillip Richard Perry | 6,364,328 | 3.66% |
| Mr Mark Phillip Juan | 6,051,870 | 3.48% |
| The Trust Company (Australia) Limited MOF A/C | 4,754,746 | 2.74% |
| Prof Borje Anderson | 3,778,577 | 2.17% |
| Biosynergy Partners Pty Ltd | 2,694,642 | 1.55% |
| Kudoss Investments Pty Ltd Aitken Global Family A/C | 2,073,817 | 1.19% |
| BNP Paribas Nominees Pty Ltd IB AU Noms Retailclient | 2,067,558 | 1.19% |
| Ms Marinella Messina | 1,757,377 | 1.01% |
| Mr Sandor Helby | 1,685,000 | 0.97% |
| Mr Phillip Richard Perry & Mrs Tetyana Perry Doneska Super Fund A/C | 1,660,000 | 0.96% |
| Mr Kimberley Ross Gartrell & Mrs Jennifer Margaret Gartrell K&J Gartrell Super Fund A/C | 1,575,000 | 0.91% |
| Mr Alan Giles Sauran | 1,178,168 | 0.68% |
| Citicorp Nominees Pty Limited | 1,049,427 | 0.60% |
| Surpion Pty Ltd M W Suhr & Co A/C | 1,030,000 | 0.59% |
| Mr Brian James Walker | 1,012,345 | 0.58% |
| Mr Anthony James Robinson The Peeko Family No 86 A/C | 954,290 | 0.55% |
| Mr Van Quy Do | 930,371 | 0.54% |
| Mr Beau Thomas Robinson Beau Robinson Invstmnt A/C | 752,045 | 0.43% |
| 3rd Man Risk Consulting Pty Limited | 745,250 | 0.43% |
